Abstract:Background: Hepatitis B, a vaccine-preventable liver infection, remains a global public health problem. Dedicated groups of experts and funding are focusing on achieving a functional cure to eradicate this disease by 2030. Areas of Uncertainty: With more than 40 molecules available or under investigation as new treatments for hepatitis B virus (HBV) infection, none of them is curative so far. Available treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular carcinoma, and death, but do not eliminate the virus, and the risk of hepatocellular carcinoma remains. Nucleoside/nucleotide analogs are recommended as first-line therapy for patients with chronic hepatitis B infection to inhibit viral replication and lower the HBV DNA values, but long-term therapy is usually needed to maintain suppression. Cessation of the therapy in accordance with clinical guidelines can result in virological and clinical relapse. Data Sources: PubMed, Web of Science, clinicaltrials.gov, and gray literature sources were searched for articles discussing HBV management and new therapies. Results: With current nucleoside/nucleotide analog therapies, fewer than 5% of patients lose hepatitis B surface antigen after 12 months, which underscores the need for new drugs that can achieve a functional cure. New therapies are being developed, including small interfering RNAs. Bepirovirsen, a modified antisense oligonucleotide, shows promising results and a good safety profile, but requires further exploration in larger number of patients to determine whether a functional cure is possible. Conclusions: Eradication of HBV infection with currently available therapies is not yet possible. Experts are developing innovative treatments, such as bepirovirsen, to achieve functional cure for this disease and to reduce morbidity and mortality associated with hepatic cirrhosis and hepatocellular carcinoma.

Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers

Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management

HBV Biomarkers and Their Role in Guiding Treatment Decisions

Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection

[Application of the New Serum Markers in the Research and Development of Innovative Hepatitis B Drugs].

Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection

Emerging Biomarkers for HBV Cure: HBsAg and Beyond

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

[Research progress of biomarkers of hepatitis B virus and clinical significance]

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Advances in treatment and prevention of hepatitis B

Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B

New viral biomarkers for Hepatitis B: Are we able to change practice?

Advances in Hepatitis B Treatment

Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection

Advances in the Pharmacological Management of Chronic Hepatitis B

Global importance of new treatment strategies to efforts to control hepatitis B virus

Emerging drugs for the treatment of hepatitis B

Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?

Getting to HBV cure: The promising paths forward